Pharma BD Deal Intelligence
A $2.4B cash acquisition of Shire's oncology business that gave Servier its first US commercial presence and became the foundation for Tibsovo, Voranigo, and Ojemda. Oncaspar and Onivyde grew steadily post-close, with the resulting US subsidiary reaching €1.496B in FY2024/25 revenue.
Not just a good deal — the deal that created Servier's entire US oncology business, now generating well over $1.6B/year
Full analysis, sources & comparables →BioPharma Dive cited Jefferies' Peter Welford on strategic logic and Cowen's Ken Cacciatore arguing that divesting just 2% of revenues was unlikely to deter a…
Coverage framed the timing as Shire monetizing a non-core franchise at a 9.2x revenue multiple ahead of Takeda's potential offer — a clean asset sale that also…
Peer-reviewed FDA Approval Summary: calaspargase pegol-mknl (Asparlas) approved Dec 20, 2018 for pediatric/young-adult ALL (ages 1 month-21 yrs) under Servier…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Servier acquired Shire's global oncology business for $2.4B cash, announced April 16, 2018 and completed August 31, 2018. Includes Oncaspar (pegaspargase, ALL), Onivyde ex-US (liposomal irinotecan, metastatic pancreatic cancer), calaspargase pegol (NDA pending at deal time; subsequently FDA-approved as Asparlas on December 20, 2018 under Servier Pharmaceuticals LLC), and two early-stage immuno-oncology collaborations. Establishes Servier's first direct US commercial presence via newly formed Servier Pharmaceuticals LLC in Boston. Revenue multiple of 9.2x 2017 sales of $262M.
Not just a good deal — the deal that created Servier's entire US oncology business, now generating well over $1.6B/year
Assessment window: 5yr post-close.
6K US cases/yr · $262M Shire oncology business 2017 revenue (Oncaspar + Onivyde ex-US)
Acute lymphoblastic leukemia is the most common pediatric cancer, accounting for ~20% of cancer in patients under 20, with ~6,250 new US cases annually across all ages. Asparaginase therapy is a backbone of multi-agent ALL chemotherapy regimens — leukemic blasts cannot synthesize asparagine and depend on extracellular supply, which the enzyme depletes. Adult ALL outcomes lag pediatric, with five-year survival under 40% in older adults.
ALL induction/consolidation regimens use one of three asparaginase formulations: native E. coli asparaginase (largely discontinued in US), Erwinia chrysanthemi asparaginase (Erwinaze, Jazz Pharmaceuticals — used after E. coli hypersensitivity), and PEGylated forms. Oncaspar (pegaspargase) was the dominant first-line PEGylated asparaginase at deal time, with Calaspargase pegol (later Asparlas) under FDA review as a longer-acting next-gen successor (approved December 2018). Servier's deal also included ex-US Onivyde (liposomal irinotecan) for second-line metastatic pancreatic cancer, where it competed with FOLFIRINOX, gemcitabine/abraxane, and was later expanded to first-line via the NAPOLI-3 trial NALIRIFOX regimen (FDA approval February 2024). On the ALL side, Servier's portfolio later faced pressure from Jazz's Rylaze (recombinant Erwinia, approved June 2021) entering the second-line slot. Strategically the deal gave Servier its first direct US commercial presence — the new Servier Pharmaceuticals LLC in Boston — at a 9.2x 2017 revenue multiple ($2.4B against $262M in 2017 sales), a steep but defensible price for the platform value.
On Dec 20, 2018 — ~4 months after deal close — the FDA approved Asparlas (calaspargase pegol-mknl) under Servier Pharmaceuticals LLC for ALL in pediatric and young-adult patients (1 month-21 yrs), with a longer (q21d) dosing interval. The asset was NDA-pending at deal announcement; its approval validated the acquisition thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Shire plc (Oncology Business) (this deal) | 2018 | $2.4B | 88 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Aitia | 2024 | — | — |
| Servier / AmoyDx | 2024 | — | — |
| Servier / kyron.bio | 2026 | — | — |
← Browse all deals · How we score deals
More: 2018 deals · Servier deals · Hematology deals